Notably, treatment with LRRK2 kinase inhibitor also increases GCase activity in DA neurons derived from healthy controls and from PD patients with heterozygous GBA mutation, suggesting that LRRK2 kinase regulates GCase activity irrespective of the mutation status or the disease state [14]. This evidence concerns the gene LRRK2 and Parkinson disease.